NCT06165965View on ClinicalTrials.gov

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

June 13, 2022

Study Completion Date

June 27, 2022

Conditions
Healthy Adult
Interventions
DRUG

SGLT2 inhibitor

SGLT2 dual inhibitor

Trial Locations (1)

13497

Bundang CHA university global clinical trials center Institutional Review Board, Gyeonggi-do

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY